This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Borgoño, C. A. Articles by Diamandis, E. P. Search for Related Content PubMed PubMed Citation Articles by Borgoño, C. A. Articles by Diamandis, E. P. Related Collections Tumor Biology: Invasion and Metastasis Therapeutics and Targets Therapeutics and Targets: Identification, Validation, and Markers

---

Subject Review

Human Tissue Kallikreins: Physiologic Roles and Applications in Cancer

Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, and Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada

Requests for reprints: Eleftherios P. Diamandis, Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, 600 University Avenue, Toronto, Ontario, M5G 1X5 Canada. Phone: (416) 586-8443; Fax: (416) 586-8628. E-mail: ediamandis{at}mtsinai.on.ca

Abstract

Tissue kallikreins are members of the S1 family (clan SA) of trypsin-like serine proteases and are present in at least six mammalian orders. In humans, tissue kallikreins (hK) are encoded by 15 structurally similar, steroid hormone–regulated genes (KLK) that colocalize to chromosome 19q13.4, representing the largest cluster of contiguous protease genes in the entire genome. hKs are widely expressed in diverse tissues and implicated in a range of normal physiologic functions from the regulation of blood pressure and electrolyte balance to tissue remodeling, prohormone processing, neural plasticity, and skin desquamation. Several lines of evidence suggest that hKs may be involved in cascade reactions and that cross-talk may exist with proteases of other catalytic classes. The proteolytic activity of hKs is regulated in several ways including zymogen activation, endogenous inhibitors, such as serpins, and via internal (auto)cleavage leading to inactivation. Dysregulated hK expression is associated with multiple diseases, primarily cancer. As a consequence, many kallikreins, in addition to hK3/PSA, have been identified as promising diagnostic and/or prognostic biomarkers for several cancer types, including ovarian, breast, and prostate. Recent data also suggest that hKs may be causally involved in carcinogenesis, particularly in tumor metastasis and invasion, and, thus, may represent attractive drug targets to consider for therapeutic intervention.

Key Words: serine proteases • tissue kallikreins • cancer biomarkers • prognostic markers

This article has been cited by other articles:

				H.-X. Li, B.-Y. Hwang, G. Laxmikanthan, S. I. Blaber, M. Blaber, P. A. Golubkov, P. Ren, B. L. Iverson, and G. Georgiou Substrate specificity of human kallikreins 1 and 6 determined by phage display Protein Sci., April 1, 2008; 17(4): 664 - 672. [Abstract] [Full Text] [PDF]

				N. Emami and E. P. Diamandis Human Kallikrein-related Peptidase 14 (KLK14) Is a New Activator Component of the KLK Proteolytic Cascade: POSSIBLE FUNCTION IN SEMINAL PLASMA AND SKIN J. Biol. Chem., February 8, 2008; 283(6): 3031 - 3041. [Abstract] [Full Text] [PDF]

				T. W. Stief Kallikrein Activates Prothrombin Clinical and Applied Thrombosis/Hemostasis, January 1, 2008; 14(1): 97 - 98. [Abstract] [PDF]

				R. Salani, B. Davidson, M. Fiegl, C. Marth, E. Muller-Holzner, G. Gastl, H.-Y. Huang, J.-C. Hsiao, H.-S. Lin, T.-L. Wang, et al. Measurement of Cyclin E Genomic Copy Number and Strand Length in Cell-Free DNA Distinguish Malignant versus Benign Effusions Clin. Cancer Res., October 1, 2007; 13(19): 5805 - 5809. [Abstract] [Full Text] [PDF]

				S. Weinsheimer, K. A.B. Goddard, A. R. Parrado, Q. Lu, M. Sinha, E. R. Lebedeva, A. Ronkainen, M. Niemela, E. K. Khusnutdinova, R. I. Khusainova, et al. Association of Kallikrein Gene Polymorphisms With Intracranial Aneurysms Stroke, October 1, 2007; 38(10): 2670 - 2676. [Abstract] [Full Text] [PDF]

				M. W. McIntosh, Y. Liu, C. Drescher, N. Urban, and E. P. Diamandis Validation and Characterization of Human Kallikrein 11 as a Serum Marker for Diagnosis of Ovarian Carcinoma Clin. Cancer Res., August 1, 2007; 13(15): 4422 - 4428. [Abstract] [Full Text] [PDF]

				J. L.V. Shaw and E. P. Diamandis Distribution of 15 Human Kallikreins in Tissues and Biological Fluids Clin. Chem., August 1, 2007; 53(8): 1423 - 1432. [Abstract] [Full Text] [PDF]

				Q. Luo, L. Siconolfi-Baez, P. Annamaneni, M. T. Bielawski, P. M. Novikoff, and R. H. Angeletti Altered protein expression at early-stage rat hepatic neoplasia Am J Physiol Gastrointest Liver Physiol, May 1, 2007; 292(5): G1272 - G1282. [Abstract] [Full Text] [PDF]

				J. Dorn, M. Schmitt, R. Kates, B. Schmalfeldt, M. Kiechle, A. Scorilas, E. P. Diamandis, and N. Harbeck Primary Tumor Levels of Human Tissue Kallikreins Affect Surgical Success and Survival in Ovarian Cancer Patients Clin. Cancer Res., March 15, 2007; 13(6): 1742 - 1748. [Abstract] [Full Text] [PDF]

				B. Hurle, W. Swanson, NISC Comparative Sequencing Program, and E. D. Green Comparative sequence analyses reveal rapid and divergent evolutionary changes of the WFDC locus in the primate lineage Genome Res., March 1, 2007; 17(3): 276 - 286. [Abstract] [Full Text] [PDF]

				C. A. Borgono, I. P. Michael, N. Komatsu, A. Jayakumar, R. Kapadia, G. L. Clayman, G. Sotiropoulou, and E. P. Diamandis A Potential Role for Multiple Tissue Kallikrein Serine Proteases in Epidermal Desquamation J. Biol. Chem., February 9, 2007; 282(6): 3640 - 3652. [Abstract] [Full Text] [PDF]

				C. A. Borgono, I. P. Michael, J. L. V. Shaw, L.-Y. Luo, M. C. Ghosh, A. Soosaipillai, L. Grass, D. Katsaros, and E. P. Diamandis Expression and Functional Characterization of the Cancer-related Serine Protease, Human Tissue Kallikrein 14 J. Biol. Chem., January 26, 2007; 282(4): 2405 - 2422. [Abstract] [Full Text] [PDF]

				K. Oikonomopoulou, K. K. Hansen, M. Saifeddine, I. Tea, M. Blaber, S. I. Blaber, I. Scarisbrick, P. Andrade-Gordon, G. S. Cottrell, N. W. Bunnett, et al. Proteinase-activated Receptors, Targets for Kallikrein Signaling J. Biol. Chem., October 27, 2006; 281(43): 32095 - 32112. [Abstract] [Full Text] [PDF]

				M. Debela, V. Magdolen, N. Schechter, M. Valachova, F. Lottspeich, C. S. Craik, Y. Choe, W. Bode, and P. Goettig Specificity Profiling of Seven Human Tissue Kallikreins Reveals Individual Subsite Preferences J. Biol. Chem., September 1, 2006; 281(35): 25678 - 25688. [Abstract] [Full Text] [PDF]

				M. H. Slagter, L. J.G. Gooren, A. Scorilas, C. D. Petraki, and E. P. Diamandis Effects of Long-term Androgen Administration on Breast Tissue of Female-to-Male Transsexuals J. Histochem. Cytochem., August 1, 2006; 54(8): 905 - 910. [Abstract] [Full Text] [PDF]

				D. Talantov, J. Baden, T. Jatkoe, K. Hahn, J. Yu, Y. Rajpurohit, Y. Jiang, C. Choi, J. S. Ross, D. Atkins, et al. A Quantitative Reverse Transcriptase-Polymerase Chain Reaction Assay to Identify Metastatic Carcinoma Tissue of Origin J. Mol. Diagn., July 1, 2006; 8(3): 320 - 329. [Abstract] [Full Text] [PDF]

				M. H. Slagter, L. J.G. Gooren, W. de Ronde, A. Soosaipillai, A. Scorilas, E. J. Giltay, M. Paliouras, and E. P. Diamandis Serum and Urine Tissue Kallikrein Concentrations in Male-to-Female Transsexuals Treated with Antiandrogens and Estrogens Clin. Chem., July 1, 2006; 52(7): 1356 - 1365. [Abstract] [Full Text] [PDF]

				I. P. Michael, G. Pampalakis, S. D. Mikolajczyk, J. Malm, G. Sotiropoulou, and E. P. Diamandis Human Tissue Kallikrein 5 Is a Member of a Proteolytic Cascade Pathway Involved in Seminal Clot Liquefaction and Potentially in Prostate Cancer Progression J. Biol. Chem., May 5, 2006; 281(18): 12743 - 12750. [Abstract] [Full Text] [PDF]

				M.R. Darling, L. Jackson-Boeters, T.D. Daley, and E.P. Diamandis Human Kallikrein 6 Expression in Salivary Gland Tumors J. Histochem. Cytochem., March 1, 2006; 54(3): 337 - 342. [Abstract] [Full Text] [PDF]

				J. M. Chirgwin and T. A. Guise Does Prostate-Specific Antigen Contribute to Bone Metastases? Clin. Cancer Res., March 1, 2006; 12(5): 1395 - 1397. [Full Text] [PDF]

				C. A. Borgono, T. Kishi, A. Scorilas, N. Harbeck, J. Dorn, B. Schmalfeldt, M. Schmitt, and E. P. Diamandis Human Kallikrein 8 Protein Is a Favorable Prognostic Marker in Ovarian Cancer Clin. Cancer Res., March 1, 2006; 12(5): 1487 - 1493. [Abstract] [Full Text] [PDF]

				H. Nagahara, K. Mimori, T. Utsunomiya, G. F. Barnard, M. Ohira, K. Hirakawa, and M. Mori Clinicopathologic and Biological Significance of Kallikrein 6 Overexpression in Human Gastric Cancer Clin. Cancer Res., October 1, 2005; 11(19): 6800 - 6806. [Abstract] [Full Text] [PDF]

				A. D. Santin, E. P. Diamandis, S. Bellone, A. Soosaipillai, S. Cane, M. Palmieri, A. Burnett, J. J. Roman, and S. Pecorelli Human Kallikrein 6: A New Potential Serum Biomarker for Uterine Serous Papillary Cancer Clin. Cancer Res., May 1, 2005; 11(9): 3320 - 3325. [Abstract] [Full Text] [PDF]

				I. P. Michael, G. Sotiropoulou, G. Pampalakis, A. Magklara, M. Ghosh, G. Wasney, and E. P. Diamandis Biochemical and Enzymatic Characterization of Human Kallikrein 5 (hK5), a Novel Serine Protease Potentially Involved in Cancer Progression J. Biol. Chem., April 15, 2005; 280(15): 14628 - 14635. [Abstract] [Full Text] [PDF]

				K. Ogawa, T. Utsunomiya, K. Mimori, F. Tanaka, H. Inoue, H. Nagahara, S. Murayama, and M. Mori Clinical Significance of Human Kallikrein Gene 6 Messenger RNA Expression in Colorectal Cancer Clin. Cancer Res., April 15, 2005; 11(8): 2889 - 2893. [Abstract] [Full Text] [PDF]

				I. P. Michael, L. Kurlender, N. Memari, G. M. Yousef, D. Du, L. Grass, C. Stephan, K. Jung, and E. P. Diamandis Intron Retention: A Common Splicing Event within the Human Kallikrein Gene Family Clin. Chem., March 1, 2005; 51(3): 506 - 515. [Abstract] [Full Text] [PDF]